Pathology: metastatic/advanced RCC (mRCC) - 1st line (L1); mRCC - L1 - PDL1 positive;
metastatic/advanced RCC (mRCC) - 1st line (L1) | mRCC - L1 - PDL1 positive | ||
JAVELIN Renal 101 (all population), 2019 | JAVELIN Renal 101( PDL1>1%), 2019 | ||
avelumab plus axitinib | 2 | T1 | T1 |
sunitinib | 0 | T0 | T0 |